Effect of Silibinin in Human Colorectal Cancer Cells: Targeting the Activation of NF-κB Signaling
Overview
Oncology
Authors
Affiliations
Chronic inflammation is one of the primary causes of colorectal cancer (CRC), and major inflammatory pathways implicated in CRC are cyclooxygenase-2 (COX-2) and iNOS; both regulated by nuclear factor-kappa B (NF-κB) suggesting that inhibitors of these pathways could be ideal against CRC. Silibinin has shown promising efficacy against various malignancies including CRC, and therefore here we assessed whether silibinin targets NF-κB activation and associated signaling as a mechanism of its anti-inflammatory and anti-cancer effects in CRC. Our results indicated that silibinin treatment (50-200 µM) of human CRC SW480, LoVo, and HT29 cells strongly inhibits tumor necrosis factor α-induced NF-κB activation together with decreased nuclear levels of both p65 and p50 sub-units. Silibinin also significantly increased IκBα level with a concomitant decrease in phospho-IκBα, without any effect on TNFR1, TRADD, and RIP2, indicating its inhibitory effect on IκB kinase α activity. Next we assessed the effect of oral silibinin feeding on NF-κB pathway in SW480 (COX-2 negative) and LoVo (COX-2 positive) tumor xenografts in nude mice. Together with its inhibitory efficacy on tumor growth and progression, silibinin inhibited NF-κB activation in both xenografts. The protein levels of various NF-κB-regulated molecules such as Bcl-2, COX-2, iNOS, VEGF, and MMPs were also decreased by silibinin in both cell culture studies and xenograft analyses, suggesting its potential to alter NF-κB transcriptional activity. Together, these findings are highly significant in establishing for the first time that silibinin suppresses CRC growth and progression possibly through its anti-inflammatory activity by interfering with NF-κB activation and thus has potential against human CRC.
Ding Y, Yu Y Mol Med Rep. 2025; 31(4).
PMID: 40017144 PMC: 11884236. DOI: 10.3892/mmr.2025.13474.
Smeu A, Marcovici I, Dehelean C, Dumitrel S, Borza C, Lighezan R Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40006045 PMC: 11858883. DOI: 10.3390/ph18020231.
Deshmukh R, Prajapati M, Harwansh R Curr Pharm Biotechnol. 2024; 25(5):599-622.
PMID: 38807329 DOI: 10.2174/0113892010242028231002075512.
Silymarin and Inflammation: Food for Thoughts.
Surai P, Surai A, Earle-Payne K Antioxidants (Basel). 2024; 13(1).
PMID: 38247522 PMC: 10812610. DOI: 10.3390/antiox13010098.
Bioactive Compounds of Dietary Origin and Their Influence on Colorectal Cancer as Chemoprevention.
Delgado-Gonzalez P, Garza-Trevino E, de la Garza Kalife D, Quiroz Reyes A, Hernandez-Tobias E Life (Basel). 2023; 13(10).
PMID: 37895359 PMC: 10608661. DOI: 10.3390/life13101977.